Correction: Alfaro-Arnedo et al. IGF1R as a Potential Pharmacological Target in Allergic Asthma. Biomedicines 2021, 9, 912

Figure 4. Therapeutic inhibition of IGF1R attenuates AHR and normalizes pulmonary surfactant expression upon HDM-induced allergy. (A) Quantification of lung resistance (LR) and dynamic compliance (Cdyn) to methacholine (MCh) evaluated by plethysmography (n = 4–8 mice per group) and (B) changes in lung tissue mRNA expression surfactant (Sftp) markers Sftpa1, b c, and d, normalized to 18S expression in HDM-challenged mice treated with NVP vs. controls (n = 5 mice per group). (C) Representative immunostains for SFTPC (green) (white arrowheads), and quantification of the number of SFTPC⁺ cells per unit area (mm²) in lung sections from HDM-challenged mice treated with NVP vs. controls (n = 5–10 mice per group; scale bar: 50 µm). Data are expressed as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; # p < 0.05 (comparisons within the same group) (Mann–Whitney U test or Student’s t-test for comparing two groups and Kruskal–Wallis test or ANOVA multiple comparison test for grouped or multivariate analysis).